Edit
SciClone Pharmaceuticals
http://www.sciclone.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 29.09.2025
Active
赛生药业,SciClone,赛生药业控股有限公司,SciClone Pharmaceuticals (Holdings) Limited
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Mentions in press and media 7
| Date | Title | Description |
| 29.09.2025 | ADIA takes lead role in GL Capital’s continuation vehicle for SciClone | GL Capital has brought in a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) as lead investor in a single-asset continuation vehicle (CV), according to a release on Monday. The vehicle will house SciClone Pharmaceuticals... |
| 08.11.2023 | Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer | ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. ESR1 mutati... |
| 20.09.2022 | Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections | Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in China The deal brings together Melinta's innovation, Menarini's c... |
| 23.04.2021 | SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED SciClone Pharmaceuticals : Voluntary Announcement - Formation of the Strategic Cooperation with SF Pharmaceuticals to Create One-Stop F2C Supply Chain Solu... | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 29.12.2020 | SciClone se incorpora al capital de AbilityPharma, participada por Inveready, Fitalent, Sodena y el CDTI, con un compromiso de inversión de $3M | 29/12/2020 Nota de prensa SCICLONE SE INCORPORA AL CAPITAL DE ABILITYPHARMA, PARTICIPADA POR INVEREADY, FITALENT, SODENA Y EL CDTI, CON UN COMPROMISO DE INVERSIÓN DE $3 MILLONES. La empresa biofarmacéutica catalana AbilityPharma, centrad... |
| 17.10.2017 | Chinese consortium completes $605m buyout of Nasdaq-listed SciClone Pharma | Premium Nasdaq-listed SciClone Pharmaceuticals Inc. has been privatised and delisted from the New York-based stock exchange by a consortium consisting of entities affiliated with GL Capital Management GP Limited (GL Capital), Bank of China ... |
| 08.06.2017 | Term Sheet — Thursday, June 8 | You’ll Laugh! Cry! (Maybe Buy.) Below is my column from the latest issue of Fortune. Apologies if this concept sounds a tiny bit familiar to dedicated Term Sheet readers… Paid Content You can't secure what you can't see From ExtraHop Some o... |